Article Information
History
- May 31, 2020.
Article Versions
- Version 1 (April 2, 2020 - 08:39).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Kartik Sehgal, M.B.B.S.a,#,
- Anushi Bulumulle, MDb,c,
- Heather Brody, MDb,c,
- Ritu R. Gill, MD, MPHd,
- Shravanti Macherla, MDb,c,
- Aleksandra Qilleria,
- Danielle C. McDonald, NP, MSNa,
- Cynthia R. Cherry, MSN-AGNPc,
- Meghan Shea, MDa,
- Mark S. Huberman, MDa,
- Paul A. VanderLaan, MD, PhDe,
- Glen J. Weiss, MD, MBAa,1,
- Paul R. Walker, MD, FACPb,
- Daniel B. Costa, MD, PhDa and
- Deepa Rangachari, MDa,#
- aDivision of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
- bDivision of Hematology and Oncology, Department of Internal Medicine, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USA
- cVidant Medical Center, Greenville, NC 27834, USA
- dDepartment of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
- eDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
- ↵#Corresponding Authors:
Kartik Sehgal, MBBS, Beth Israel Deaconess Medical Center, 330 Brookline Avenue-Shapiro 9, Boston, MA 02215, USA (ksehgal{at}bidmc.harvard.edu). Tel: 617-667-1901, Fax: 617-667-2518. #Deepa Rangachari, MD, Beth Israel Deaconess Medical Center, 330 Brookline Avenue-Shapiro 9, Boston, MA 02215, USA (drangach{at}bidmc.harvard.edu). Tel: 617-667-1901, Fax: 617-667-2518.
Posted May 31, 2020.
Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small cell lung cancer
